Mylan biosim ready to challenge Amgen blockbuster Neulasta by Eric Sagonowsky Tuesday, June 5, 2018 Amgen's $3.9 billion Neulasta, one of the biggest drug targets for biosim developers, is finally slated to face competition after a 2015 patent loss.
Patent fights jump in 2017, led by Eli Lilly, Pfizer, Sanofi and more by Eric Sagonowsky Friday, May 4, 2018 Top drugmakers made more trips to the courthouse last year, aiming to blockade big-selling drugs against generic competitors.
Amgen, Sandoz trial over Enbrel patents delayed, filings suggest by Eric Sagonowsky Monday, April 2, 2018 Sandoz may have to wait a little longer for a clear shot at launching a biosimilar to Amgen's anti-inflammatory blockbuster Enbrel.
Amgen faces one-two blow from Repatha, Sensipar competition by Arlene Weintraub Tuesday, March 13, 2018 Amgen faces generic competition to its thyroid medication, Sensipar, and the potential to lose share in the PCSK9 cholesterol drug market. Now what?
Amgen comes up short in Sensipar lawsuit against FDA by Eric Sagonowsky Wednesday, February 21, 2018 With Sensipar's patent expiration nearing, Amgen failed in its court battle to win six months of extra protection against generics.
Amgen sinks after Q4 earnings miss despite tax benefits by Arlene Weintraub Friday, February 2, 2018 Several pharma companies have thrilled investors with their sunny predictions—but not Amgen.
